• Printer Friendly Version
  • Decrease Text Size
  • Increase Text Size
  • PDF
Thursday, August 6, 2015

Westchester Medical Center Performs First Evolut R CoreValve Implant in Transcatheter Aortic Valve Replacement (TAVR)

CONTACT:  David Billig             (914) 493 8028 

Westchester Medical Center (WMC) recently announced that it is the first hospital in the Hudson Valley region and one of the first in the country, to offer minimally invasive transcatheter aortic valve replacement (TAVR) with the newest approved transcatheter heart valve: the Medtronic CoreValve Evolut R. 

The CoreValve Evolut R can be fully recaptured, the first transcatheter valve approved by the FDA to offer such a novel and innovative feature.  This allows surgeons and cardiologists the ability to reposition the valve, if needed, for optimal deployment.  The Transcatheter Heart Team at Westchester performed the first two implants on Wednesday, July 29th, under IV sedation and local anesthesia.  Both patients went home uneventfully within 4 days of having the procedure.

“The newer Evolut R valve, with a smaller delivery catheter, allows patients with leg arteries previously too small for CoreValve to now be implanted from the groin.” said Dr. Gilbert Tang, Director of Valve Disease Center at WMC. “The recapturable feature of the Device also allows us to implant the valve with better precision than before, potentially reducing the risk of needing to implant a permanent pacemaker.  Our team’s superb results with the earlier generation CoreValve allowed us to implant the newer valve ahead of many Evolut R clinical trial sites.  We are very excited to be one of the first in the country offering the latest technology in TAVR to our patients.”

To inquire more about TAVR at Westchester Medical Center, contact the Valve Program Hotline at (914)830-1098 or e-mail HeartValve@wcmc.com